Truist raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be “poised to heat up”.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- FDA says Boston Scientific Accolade pacemakers may need early replacement
- Boston Scientific price target raised to $110 from $100 at TD Cowen
- Boston Scientific price target raised to $107 from $98 at Citi
- Boston Scientific price target raised to $101 from $98 at Canaccord
- Boston Scientific participates in a conference call with Truist